Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of ...

Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.

Timings are approximate. For a full description of the appraisal process, please see our Health Technology Evaluation manual. Topics are referred to us by ministers following the topic selection ...

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Technology appraisal guidance TA559 Published: 23 ...

COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 NICE guideline NG186 Published: 20 November 2020 ...